ArticleCureus2025
A Case of Late-Onset Acute Pulmonary Sarcoidosis Exacerbation After 26 Years of Clinical Stability.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary sarcoidosis is a systemic granulomatous disease with a variable clinical course. While many cases resolve spontaneously, a subset of patients may develop chronic disease or experience acute pulmonary exacerbations. Such exacerbations typically occur within the first decade after diagnosis, and late-onset exacerbations after a prolonged quiescent phase are exceedingly rare. We present the case of a 59-year-old Japanese man who developed acute pulmonary exacerbation of sarcoidosis (APES) 26 years after being diagnosed with stage I disease. He had remained clinically stable without systemic treatment and had only been followed for ocular involvement. He presented with progressive exertional dyspnea over four months, followed by fever and resting dyspnea. High-resolution computed tomography revealed bilateral ground-glass opacities, mediastinal lymphadenopathy, and traction bronchiectasis. Laboratory tests showed elevated lactate dehydrogenase (LDH), Krebs von den Lungen-6 (KL-6), and soluble interleukin-2 receptor (sIL-2R) levels. Bronchoalveolar lavage demonstrated lymphocytosis, and transbronchial lung cryobiopsy confirmed non-caseating granulomas. Infectious and autoimmune etiologies were excluded. The patient was diagnosed with APES and treated with systemic corticosteroids, including an initial pulse therapy followed by tapering oral prednisolone. His oxygenation improved significantly, and supplemental oxygen was no longer required at rest by hospital day 24, although desaturation persisted with exertion. Follow-up imaging showed partial radiologic improvement, along with newly developed pneumomediastinum. This case underscores the potential for sarcoidosis to reactivate even after decades of clinical remission. Long-term follow-up is essential, particularly in patients with fibrotic changes or extrapulmonary involvement. Early recognition and prompt management of late-onset APES may help prevent irreversible pulmonary damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.